A More Nuanced Conversation About China and Biotech
Our goal at BridgeCross is to provide audiences with an accurate, contextual understanding of China’s biotech and medtech landscape. We are neither pro- nor anti-China. We do not aim to hype, nor to vilify. We believe that good reporting, like good science, should follow the data.
What You Can Expect From BridgeCross
At BridgeCross, we are committed to:
- Independent analysis: Our content is editorially independent, and we do not accept funding from any government or political entity.
- On-the-ground insight: Our contributors have worked, lived, and built careers within China’s science ecosystem. We understand the context - both technical and cultural.
- Global relevance: Whether you're in Berlin, Boston, or Bangalore, China's biotech policies, companies, and technologies will likely shape your scientific or commercial decisions in the decade ahead.
Team
Matt Marlowe, Director, Founder
Matt Marlowe is a marketing strategist specialised in helping life science and biotech teams turn complex science into clear, commercial narratives. With deep experience in genomics and molecular diagnostics, Matthew partners with founders and product leaders to position offerings, accelerate adoption, and drive measurable market traction.
LinkedIn
Qian Mao, Consultant
Qian Mao is a seasoned life sciences and genomics expert with over 15 years of experience in molecular diagnostics, in-vitro diagnostics (IVD), and global healthcare market expansion.
Her expertise covers the full spectrum of product and partner lifecycle management - from R&D alignment and regulatory strategy to channel enablement, KOL engagement, and post-market support. Over the years, she has cultivated strategic partnerships with leading institutions and multiple national health ministries, driving impactful genomic and public health initiatives worldwide.
Please get in touch with any questions or to enquire about working with us.